Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

332
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
332
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

77
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
77
Drug Regulation01:25

Drug Regulation

3.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.3K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

2.0K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
2.0K
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.5K
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

357
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
357

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmaceutical Approval Update.

P & T : a peer-reviewed journal for formulary management·2015
Same author

Long-Acting Therapies Will Expand Growth Hormone Deficiency Market.

P & T : a peer-reviewed journal for formulary management·2015
Same author

Pharmaceutical Approval Update.

P & T : a peer-reviewed journal for formulary management·2015
Same author

Pharmaceutical Approval Update.

P & T : a peer-reviewed journal for formulary management·2015
Same author

Multiple Sclerosis: Progress, but No Cure.

P & T : a peer-reviewed journal for formulary management·2015
Same author

Pharmaceutical Approval Update.

P & T : a peer-reviewed journal for formulary management·2015

Related Experiment Video

Updated: Apr 12, 2026

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

4.7K

Pharmaceutical approval update.

Kunj Gohil

    P & T : a Peer-Reviewed Journal for Formulary Management
    |May 20, 2015
    PubMed
    Summary
    This summary is machine-generated.

    This summary covers three cancer therapies: Zarxio to prevent chemotherapy infections, Unituxin for pediatric neuroblastoma, and Farydak for multiple myeloma. These treatments target specific cancers and their complications.

    More Related Videos

    Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
    05:10

    Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

    Published on: December 11, 2016

    10.3K
    Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
    06:34

    Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

    Published on: November 29, 2024

    689

    Related Experiment Videos

    Last Updated: Apr 12, 2026

    Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
    09:30

    Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

    Published on: March 17, 2023

    4.7K
    Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
    05:10

    Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

    Published on: December 11, 2016

    10.3K
    Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
    06:34

    Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

    Published on: November 29, 2024

    689

    Area of Science:

    • Oncology
    • Pharmacology
    • Hematology

    Background:

    • Chemotherapy can lead to infections, requiring supportive care.
    • High-risk pediatric neuroblastoma presents significant treatment challenges.
    • Multiple myeloma is a complex plasma cell disorder requiring advanced therapies.

    Purpose of the Study:

    • To review the indications for Filgrastim-sndz (Zarxio) in preventing chemotherapy-induced infections.
    • To discuss the use of Dinutuximab (Unituxin) in treating high-risk pediatric neuroblastoma.
    • To outline the application of Panobinostat (Farydak) in managing multiple myeloma.

    Main Methods:

    • Literature review of clinical trial data and regulatory approvals.
    • Analysis of treatment guidelines and efficacy studies.
    • Pharmacological profile assessment of each agent.

    Main Results:

    • Filgrastim-sndz (Zarxio) is indicated for neutropenia prophylaxis during chemotherapy.
    • Dinutuximab (Unituxin) demonstrates efficacy in high-risk neuroblastoma patients.
    • Panobinostat (Farydak) shows activity in relapsed or refractory multiple myeloma.

    Conclusions:

    • Zarxio offers a crucial supportive care option in oncology.
    • Unituxin represents a targeted therapy advancement for pediatric neuroblastoma.
    • Farydak provides a treatment option for advanced multiple myeloma cases.